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http://dx.doi.org/10.10late life. Previous studies suggest an association between depression and dementia in military veter-
ans. The most likely biologic mechanisms that may link depression and dementia amongmilitary vet-
erans include vascular disease, changes in glucocorticoid steroids and hippocampal atrophy,
deposition of b-amyloid plaques, inflammatory changes, and alterations of nerve growth factors.
In addition, military veterans often have depression comorbid with posttraumatic stress disorder or
traumatic brain injury. Therefore, in military veterans, these hypothesized biologic pathways going
from depression to dementia are more than likely influenced by trauma-related processes. Treatment
strategies for depression, posttraumatic stress disorder, or traumatic brain injury could alter these
pathways and as a result decrease the risk for dementia. Given the projected increase of dementia,
as well as the projected increase in the older segment of the veteran population, in the future, it is
critically important that we understand whether treatment for depression alone or combined with
other regimens improves cognition. In this review, we summarize the principal mechanisms of this
relationship and discuss treatment implications in military veterans.
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Depression is very common through the course of veter-
ans’ lives [1,2], whereas dementia is very common primarily
in late life. After 65 years of age, the risk of dementia is
estimated to double every 5 years [3], and among
those 90 years, the risk is estimated to increase up to
50% [4,5]. A recent study documented that among
veterans 55 years and older, patients with dysthymia and
depression were more likely to develop incident dementia
than those with no depression over 7 years of follow-upccess article under the CC BY-NC-ND license (http://
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nt matter  2014 The Alzheimer’s Association. All rights r
16/j.jalz.2014.04.007(Fig. 1) [2]. Although evidence linking depression to demen-
tia has been studied in nonveterans, similar work is limited in
older military veterans.
Given the current and projected growth of the older
segment of the veteran population [6], a better understand-
ing of the link between depression and risk of dementia is
important, especially for possible treatment and preven-
tion. However, there are several challenges to understand-
ing this link. For example, major depressive disorder is
common among patients with dementia, occurring in up
to 20% of patients with Alzheimer disease (AD) and up
to 50% of patients with vascular dementia [7–9] and,
thus, disentangling which came first can be difficult. In
addition, although depression and dementia are
considered separate clinical entities, they share some
common symptoms, such as impairment in attention and
working memory, changes in sleep patterns, and a
decrease in social and occupational function [10]. More-
over, the concept of “pseudodementia” highlights theeserved.
Fig. 1. Cumulative incidence of dementia by age and depression status in
older veterans.
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mentia [11,12]. Thus, the interrelationship of depression
and dementia is complex and sometimes
indistinguishable and this complicates the ability to
determine the exact relationship of depression to dementia.
In this article, we review current knowledge on the causes
and sequelae that may explain the relationship between
depression and risk of developing dementia in military vet-
erans. We will primarily focus on mechanisms that may un-
derlie the link between depression and dementia. In addition,
we will discuss potential implications for screening and
treatment in veteran populations.
2. Potential mechanisms
In the following section, we outline the possible biologic
links between depression and the risk of dementia. Figure 2
illustrates the primary mechanisms that may link depression
to risk of dementia among military veterans. Military veter-
ans often have depression comorbid with posttraumatic
stress disorder (PTSD) [13,14] or traumatic brain injury
(TBI) [15,16]. Thus, in military veterans, each of the
hypothesized pathways represents a mechanistic link
between depression-related processes and dementia-
specific neuropathology that are more than likely exacer-
bated by trauma-related processes. The hypothesized
pathways include: (1) vascular disease; (2) changes in gluco-
corticoid steroids and hippocampal atrophy; (3) deposition
of b-amyloid (Ab) plaques; (4) inflammatory changes; and
(5) deficits of nerve growth factors or neurotrophins.
2.1. Vascular disease
Vascular disease has the strongest evidence linking
depression and dementia, and vascular risk factors are highly
prevalent among veterans (.25%) [17,18]. This evidence is
primarily based on the “vascular depression hypothesis”
[19,20], suggesting that cerebrovascular disease
predisposes, precipitates, or perpetuates some geriatricdepressive syndromes [21,22]. A number of studies have
reported that vascular lesions as well as structural brain
changes may contribute to depression in late life [23–26].
However, whether vascular disease or vascular lesions
contribute to depression or result from depression is
debatable, because each condition is associated with an
increased risk of developing the other [27].
The pathway connecting vascular disease to dementia
through depression is probably not sequential as demonstrated
in Figure 2. There are several proposedmechanisms by which
previous depression could be related to subsequent vascular
disease, including behavioral risk factors (e.g., smoking, inac-
tivity), disruption of the hypothalamic–pituitary–adrenal
(HPA) axis and increased cortisol related to themetabolic syn-
drome, development of hypertension resulting from dysregu-
lation of normal endothelial function, and increased
proinflammatory cytokines [28]. In particular, depression is
a risk factor for bothfirst-evermyocardial infarctionand stroke
[29]. Moreover, in veterans who have a high prevalence of co-
morbid mental health disorders such as depression and PTSD,
theremaybe a greater occurrenceof vascular-related disorders
comparedwith nonveteranpopulations.Depression is a known
risk factor for cardiovascular disease [30]. In addition, PTSD
with andwithout other mental health diagnoses is highly asso-
ciated with hypertension, dyslipidemia, and diabetes in Iraq
and Afghanistan veterans [31]. Recent research has even
shown thatTBI,which is common in Iraq andAfghanistanvet-
erans and highly comorbid with depression, is associated with
subsequent ischemic stroke [32]. Moreover, there is strong ev-
idence that vascular disease promotes development of depres-
sion. Risk for depression is increased greatly after myocardial
infarction and stroke [27]. In particular, magnetic resonance
imaging studies have shown robust associations between
ischemic brain lesions and depression or depressive symptoms
in older adults [33,34]. Longitudinal studies provide evidence
that large cortical white matter lesions and severe subcortical
white matter grade are significant risk factors for developing
depressive symptoms [34]. These white matter changes have
been found to predate and predict late-life depression [34,35].
The “vascular-depression-dementia hypothesis” is also
supported by findings that indicate that vascular disease con-
tributes to the clinical manifestation of dementia symptoms
[36,37]. Ischemic damage, largely in the frontostriatal brain
regions, may lead to significant cognitive deficits [38].
Finally, the ischemic damage to frontostriatal brain regions
may explain the executive function, psychomotor slowing,
and resistance to treatment common in late-life depression
[28,38,39], which suggests that ischemic structural
changes in the brain are a common etiologic factor of both
the depression and the related cognitive impairment.2.2. Changes in glucocorticoid steroids and hippocampal
atrophy
Another proposed link between depression and dementia
may be through the increased production of cortisol resulting
Fig. 2. Mechanisms linking depression and dementia. PTSD, posttraumatic stress disorder; TBI, traumatic brain injury.
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vated by depression and depressive symptoms that increase the
production of glucocorticoids. This escalation of glucocorti-
coids leads to damage in the hippocampus as well as down-
regulationofglucocorticoid receptors (Figure2).Thenet effect
is impaired negative feedback to the HPA axis and chronic
elevation of adrenal glucocorticoids (or “glucocorticoid
cascade” [40]), ultimately resulting in a vicious cyclewith hip-
pocampus atrophy and cognitive deficits [28,41]. Impairment
in glucocorticoid metabolism (e.g., increased cortisol
bioavailability) has been documented in patients with
depression [42] and patients with dementia [43]. Additionally,
atrophy of the hippocampus is one of the early brain changes in
AD [44], and reduced hippocampal volume has been found in
patients with depression [45–47]. Furthermore, PTSD was
associated with smaller hippocampal volume and deficits in
short-term memory in 26 Vietnam combat veterans compared
with 22 subjects without psychiatric disorders [48]. Interest-
ingly, almost 100% of these veterans with PTSD had a diag-
nosis of major depression or dysthymia over their lifetime,
whereas 80% had a current comorbid diagnosis.
Animal models of the stress response have provided
much of the evidence for the cortisol-hippocampal link
and suggest that high-stress conditions or exogenous gluco-
corticoids can cause hippocampal neuronal damage [49] and
memory impairment [50] and that hippocampal damage can
accumulate over a life course of exposure to increased stress
and glucocorticoid excess [51]. A similar cycle may exist in
humans in whom there is a high correlation between expo-
sure to stressful events and depressive episodes [52–54]
and the HPA axis is hyperactive in depression [55,56].
This is particularly concerning in military veterans who
are at increased risk of exposure to trauma, and, thus,
heightened exposure to high-stress conditions, leading to
sequelae of depression as well as PTSD [57].
Studies have found that loss of hippocampal volume in-
creases the risk of cognitive decline [58,59] and evendementia [60] in adults with depression, but findings are
conflicting [61,62]. In one study, a history of depression was
not associated with hippocampal volumes at baseline, and
these volumes did not mediate the increased risk for AD
associated with prior depression [61]. This finding implies
that the effect of depression is not through hippocampal atro-
phy. In contrast, reductions in hippocampal volume have
been found more consistently among individuals with recur-
rent depression and longer duration of illness [47,63,64], or
in those with comorbid depression-PTSD, as seen in military
veterans [48], suggesting support for the cortisol-
hippocampal pathway. Among Gulf War veterans, chronic
PTSD compared with remitted PTSD was associated with
smaller hippocampal volume even after researchers adjusted
for current depression [65]. This finding suggests, along with
the findings on recurrent depression and longer duration of
depression associated with reduced hippocampal volume,
that effective treatment of mental health disorders may reverse
the reduction in hippocampal volume once symptoms remit
and the patient recovers. It is also possible that a small hippo-
campus is a risk factor for a type of depressive disorder or
PTSD that is resilient to treatment.
However, even if it is confirmed that the relationship be-
tween depression and hippocampal atrophy exists, it is un-
clear whether this association is mediated by increased
levels of cortisol [45,47]. In some studies, hippocampal
atrophy was associated with inflammatory changes and
deficits of nerve growth factors in patients with depression
and other psychiatric disorders [66–68], which suggests
that mechanisms other than or in addition to elevated
cortisol levels may be important; however, further research
is necessary to elucidate pathways.2.3. Deposition of Ab plaques
Like hippocampal atrophy, amyloid plaques in the brain
are a diagnostic feature of AD. Both Ab and tau protein
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plaques and neurofibrillary tangles, respectively [69]. Inter-
estingly, studies have shown that AD patients with depres-
sion have a greater accumulation of plaques and tangles in
the hippocampus compared with AD patients without
depression [70,71]. Furthermore, current evidence supports
the role of Ab as primary in promoting the cascade of
events that leads to neuronal death and AD [72,73]. Thus,
it is likely that depression is also linked to AD through the
formation of amyloid plaques [74].
The formation of amyloid plaques is particularly con-
cerning for military veterans, who are at high risk of TBI
and comorbid depression [75]. Recent research has shown
that TBI may accelerate the formation of AD-related pathol-
ogies. In mouse models, controlled cortical impact TBI
increased intra-axonal Ab accumulations and phospho-tau
immunoreactivity 1 and up to 7 days after impact [76].
Compared with uninjured, age-matched control patients,
survivors of a single TBI had more neurofibrillary tangles
and Ab plaques in greater density postmortem even after
almost 50 years [18]. These findings suggest that the under-
lying mechanisms resulting in neurodegenerative disease are
probably instigated or enhanced as part of the sequelae after
survival post-TBI.
Thus, depression may be part of this process, because it is
known that even single-incident, mild, “closed-head” TBI
leads to symptoms of depression [75]. Also, PTSD is a com-
mon comorbidity of military-related TBI, along with depres-
sion, particularly in severe cases [77,78]. Furthermore,
evidence is emerging that individuals who have sustained
multiple TBIs either through military service or sports
injuries are at risk of a syndrome of chronic traumatic
encephalopathy (CTE) [79,80]. CTE is characterized by
depression, impulsivity, executive dysfunction, and
dementia. The hypothetical sequence of events in both TBI
and CTE suggests that depression shares a similar disease
process that causes dementia with distinct patterns of Ab
and tau pathology [75]. A recent study of 760 US Army sol-
diers supports the importance of depression as an integral
part of the process to cognitive decline post-TBI. Milder
TBI was significantly associated with functional impairment
but not neuropsychologic consequences, whereas both
depression and PTSD were associated with several neuro-
psychologic performance deficits, and more enduring cogni-
tive compromise, as well as functional impairment [77].
Figure 2 presents two proposed pathways involving Ab.
One implicates glucocorticoid intermediaries and the other
involves depression directly. Although the nature of the rela-
tionship between depression and Ab has not been fully eluci-
dated, it is possible that increased Ab production is initiated
by the stress response associated with depression alone, or
depression comorbid with PTSD [48], and glucocorticoids
[12,41]. In animal models of AD, the administration of
stress-level glucocorticoids promotes Ab formation by
increasing steady-state levels of amyloid precursor protein
and the Ab precursor protein cleaving enzyme [81]. Incontrast, depression may influence Ab accumulation
through direct interaction with the amyloidogenic process-
ing early in AD, a process that may be linked to the seroto-
nergic system [41,82,83], or possibly head injury [75,76].
Finally, studies indicate that there is a relationship be-
tween plasma Ab levels in patients with depression and
cognitive impairment. In a cross-sectional study, a type of
amyloid-associated depression (depression with a high ratio
of plasma Ab peptide 40 [Ab40] to Ab42) was associated
with impairment on several cognitive domains, including
memory, visuospatial abilities, and executive function [84].
Thus, amyloid-associated depression may represent a pre-
clinical or prodromal depression of AD.2.4. Inflammatory changes
Research suggests that chronic inflammation has a central
role in the pathophysiology of both depression and dementia
[76,85,86]. Figure 2 presents two proposed pathways that
involve inflammatory changes within the central nervous
system. First, the increase in levels of cytokines such as
interleukin-6 and tumor necrosis factor found in depression
may lead to a decrease in anti-inflammatory and immuno-
suppressant regulation, an increase in proinflammatory
changes within the central nervous system, and ultimately
cognitive deficits and dementia [87,88]. Second,
proinflammatory cytokines interfere with serotonin
metabolism and affect synaptic plasticity and neurogenesis
in the hippocampus [12,66].
There are numerous and complex neurodegenerative path-
ways that could link depression to the inflammatory process
of proinflammatory cytokines. Moreover, PTSD, a frequent
comorbid condition in veterans with depression, also has
been linked to inflammation [89]. However, depression may
be a direct link in this pathway, because after adjustment for
depression PTSD had a less statistically significant effect on
inflammation. In studies in vitro and in vivo, Ab activates
the microglia to release proinflammatory cytokines [90],
and microglia activation has been found in patients with
mild cognitive impairment [91]. Thus, chronic inflammation
may explain why a history of depression can promote devel-
opment of dementia; however, more studies are necessary to
elucidate and confirm this link, because the role of microglial
cells and inflammation has been challenged [92].2.5. Alterations of nerve growth factors
Alterations in neurotrophic factors, including brain-
derived neurotrophic factor (BDNF), could also serve as a
link between depression and dementia (Figure 2) [12]. Neu-
rotrophins such as BDNF are a class of growth factors that
are necessary for maintenance of neuronal health and mod-
ulation of synaptic plasticity [93]. Impaired BDNF signaling
has been observed in animal models of depression [94], in
patients with depression [68,95], and in patients with AD
[96,97]. Studies also have reported decreased mRNA
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depression and among those with AD [41,68]; however,
findings have been inconsistent [98,99]. Given these
findings and the key role BDNF plays in regulating
hippocampal plasticity, BDNF along with other
neurotrophic factors like transforming growth factor-b1,
insulin-like growth factor-1, and vascular endothelial-
derived growth factor [100] are hypothesized to play a crit-
ical role in maintaining the integrity of the hippocampus and
cognitive function.3. Treatment and management implications
This review provides evidence suggesting that screening
for cognitive impairment should be a component of the man-
agement and care of veterans with depression or those re-
porting depressive symptoms. In addition, because
stakeholders and health care providers determine the most
effective health care strategies for veterans who are diag-
nosed with depression, attention to the screening, moni-
toring, and management of other psychiatric symptoms,
including, in particular, those related to PTSD and TBI,
will be paramount. It may be that effective psychiatric and
psychosocial intervention will have broad effects by not
only treating symptoms of emotional distress but also by
contributing a secondary benefit, addressing military-
related neuropsychologic decrements.
Although there is evidence to suggest that treatment of
depression in elderly patients (i.e., pharmacologic, behav-
ioral, or other modalities) improves cognition, leading to
improved memory and other cognitive performance [101–
104] and may reduce pathophysiological alterations related
to dementia [63,105–107], other studies have found that
despite successful treatment for depression, cognitive
impairment continues to persist or even develop [108–
110]. Recent work investigating the multifunctional
protein p11 provides a molecular and cellular framework
for the development of novel antidepressant therapies
[111]. Expression of p11 overlaps with brain regions that
also are implicated in the pathophysiology of depression,
as well as dementia, including the hippocampus. Although
such interventions are still in the early phases of develop-
ment, the possibility that p11 can regulate depression-like
behaviors and responses to antidepressants are promising
to future interventions that may additionally slow the pro-
gression of cognitive decline and dementia. Furthermore,
recent preliminary research shows that a change in p11 is
indicative of therapeutic benefit of an antidepressant much
earlier than clinical phenotypic change [112].
An alternative strategy to interrupting the course of
cognitive decline with depression-interventions is an inte-
grated treatment approach. A pilot study in this area has
shown promising results, where the addition of a cholines-
terase inhibitor after antidepressant medication treatment
in elderly depressed, cognitively impaired patients led to
a significant improvement in memory [113]. Anotherapproach would be to combine antidepressants with behav-
ioral interventions that may protect against cognitive decline
(e.g., exercise, cardiovascular risk modification, psychother-
apy, or rehabilitative treatment for trauma injury/exposure).
A combined treatment approach of antidepressants, cholin-
esterase inhibitors, vitamins, and diet, and lifestyle and exer-
cise modifications has been found to protract cognitive
decline over 24 months and improve memory and frontal
lobe functions [114]. Such integrated strategies hold great
promise to reducing the progression of dementia, and
possibly preventing it, especially among veterans with
depression or depressive symptoms and high rates of comor-
bidity. Thus, future studies in veterans should examine the
implication for depression modification in clinical trials,
focusing on whether simultaneous or subsequent interven-
tions have additive or multiplicative effects on cognition.
This review highlights the need for study of potential
mechanisms linking depression to dementia to target inter-
vention, prevention, and health care needs among veterans.
The most likely links are the following hypothesized mech-
anisms: (1) vascular disease; (2) changes in glucocorticoid
steroids and hippocampal atrophy; (3) deposition of Ab pla-
ques; (4) inflammatory changes; and (5) deficits of nerve
growth factors or neurotrophins. The impact of comorbid
PTSD or TBI in military veterans is unknown but likely ex-
acerbates the mechanistic link between depression-related
processes and dementia-specific neuropathology.
In summary, the veteran population is rapidly aging [6],
which coincides with the escalating dementia epidemic
[115]. As a result, studying the effects of a modifiable risk
factor like depression and its potential for dementia preven-
tion is imperative, particularly in veterans. The underlying
pathway linking depression to dementia is multifactorial
and probably not mutually exclusive, suggesting a combined
regimen as the most promising treatment approach in mili-
tary veterans.References
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